



**GAME-CHANGING
INSIGHT INTO THE
DRUG DEVELOPMENT
LANDSCAPE THAT SAVES
HUNDREDS OF MILLIONS
AND CHANGES LIVES**

TRANSFORMING CONFIDENCE IN PHARMA ASSET POTENTIAL

Evaluate
Omnium 

Evaluate Omnium

Evaluate Omnium is the first and only solution on the market that provides a complete, dynamic view of development risk and commercial return across all phases of the clinical lifecycle.


By applying proprietary methodologies and machine learning algorithms to 6 million data points and 26,000 R&D programs, Evaluate Omnium's predictive analytics fill key information gaps from Phase I onwards. As a result, it transforms accuracy and confidence when quantifying asset potential.

This unparalleled insight into drug portfolio potential at a product-specific level ensures you get invaluable access to a comprehensive suite of data, functionality and analytics for the first time. The outcome? Significantly more accurate risk and return forecasts.

Evaluate Omnium delivers:

- Industrial-scale assessment of individual drug potential
- Unique commercial coverage for early-stage and privately held assets
- Peak sales models that cover **8 times more of the market** than consensus models
- **4 times greater accuracy** when predicting which Phase 1 drugs will reach the market
- A **21% increase in accuracy** when predicting commercial returns of Phase 1 drugs

**DEVELOPED FROM 6 MILLION
DATA POINTS AND 26,000 R&D
PROGRAMMES, EVALUATE
OMNIUM DELIVERS 8 TIMES
MORE COMMERCIAL COVERAGE
FOR A GAME-CHANGING VIEW**



**WITH 88% OF DRUGS FAILING
IN DEVELOPMENT, AND ONLY
A MINORITY OF APPROVED
DRUGS DELIVERING STRONG
COMMERCIAL RETURNS, PHARMA
CURRENTLY INVESTS FAR MORE
IN CLINICAL AND COMMERCIAL
FAILURE THAN SUCCESS**

WHAT YOU CAN EXPECT FROM EVALUATE OMNIUM

Evaluate Omnimium's proprietary functionality and analytics, many of which are brand new to the market, cover the full product lifecycle. By bringing together the full depth and breadth of Evaluate's unrivalled risk and return data in a single product, Evaluate Omnimium provides a more accurate, impartial and timely view of pharma asset potential.

WITH MORE ACCURATE FORECASTING OF PRODUCT RISK, THE INDUSTRY COULD ACHIEVE ~\$375M IN COST SAVINGS FOR EACH SUCCESSFUL DRUG BROUGHT TO MARKET



OMNIUM RISK

Delivering the most accurate predictions of product-level risk, costs and timelines

Risk Insights

- Success rates
- Development timelines
- R&D costs
- Clinical outcomes
- Clinical trials
- Calendar of events

EVALUATE OMNIUM

Transforming your confidence in quantifying pharma asset potential

Evaluate Omnimium includes all Omnimium Risk and Omnimium Return data, PLUS Combined Analytics

- Risk-adjusted peak sales
- Interactive NPV analyzer
- Quick, efficient side-by-side comparisons

OMNIUM RETURN

Amplifying your insight into the commercial potential of early-stage assets

Return Insights

- Predicted peak sales
- Market dynamics
- Pricing
- Market access
- Unmet needs



THE MOST ACCURATE PREDICTIONS OF PRODUCT-LEVEL RISK, COSTS AND TIMELINES

Omnium Risk delivers critical data and insights on product risk, enabling you to predict the likelihood of success for Phase 1 assets 4 times more accurately than existing risk models – as well as project R&D costs and time to market in more detail than ever before. Key features include:

Success rates

Identifies which in-house and competitor drugs are most likely to reach market. Proprietary algorithms, powered by machine learning, enable comparisons across products and give indications to better balance portfolio risk.

Clinical outcomes

Aggregates and standardises trial outcomes, focused on the indication-specific endpoints most likely to lead to regulatory approval.

Development timelines

Predicts when key development milestones will occur, showing progress comparison against competitors and highlighting products with first-in-class potential.

Clinical trials

Tracks and integrates clinical trials from three key industry sources alongside key commercial insights, enabling company development plans and pipelines to be fully understood.

R&D costs

Provides the industry's first comprehensive clinical trial costing model, applying real-world data to over 50,000 trials, which gives a better assessment of likely costs across the development cycle.

Calendar of events

Identifies and tracks critical product lifecycles and company events, such as trial initiations and financial results, allowing efficient monitoring of key market catalysts.



AMPLIFYING YOUR INSIGHT INTO COMMERCIAL POTENTIAL

Omnium Return delivers a more complete view of the commercial potential of assets, covering all phases of clinical development. With 8 times more coverage than consensus models, it provides a credible and comprehensive assessment of product potential that is 21% more accurate in predicting the commercial return of Phase I assets when compared to calculations based on industry average benchmarks. Key features include:

Predicted peak sales

An independent and balanced view of asset potential that leverages machine learning to provide systematic, comprehensive coverage across all phases of the clinical pipeline to accurately predict the value of R&D assets.

Market access

Unique data that identifies the current market access position for US-launched products with benchmarks that help assess the implications and opportunities.

Pricing

Key pricing data to streamline research and inform pricing strategies, including consolidated US pack pricing, current cost-per-patient values and benchmarks by indication and technology.

Market dynamics

Provides time-to-peak analysis for historically launched products to enable better assessment of market impact, along with product launch planning and market exclusivity impact and expiry.

Unmet needs

Quantifies and standardises degree of unmet need within an indication, so you can rank or compare to better focus portfolio investments.



FULL MARKET COVERAGE FOR UNPRECEDENTED INSIGHT

Evaluate Omnium gives you a full view of the market, including our specific Omnium Risk and Omnium Return modules that when combined deliver exclusive analytics that give a unique insight on product potential. These features, only available in Evaluate Omnium, include:

Interactive NPV analyzer

A standardised and systematic approach to calculating a product's Net Present Value (NPV), based on discounted cash flow models for over 6,000 products. Enables easy editing of key assumptions to create custom models.

Side-by-side comparison

Unique visualisations that combine our risk and return data in a single platform for quick, efficient side-by-side comparisons.

Risk-adjusted peak sales

Combining Product Specific PTRS and Predicted Peak Sales analytics to provide a single metric for forecasting the commercial potential of pharma assets across all phases of clinical development.



Evaluate
Omnium

CREATED FROM 25 YEARS' EXPERIENCE

Evaluate Omnium is built on Evaluate's decades of experience providing the pharma industry with market-leading data analytics and consensus-based forecasting.

Evaluate Omnium harnesses Evaluate's unparalleled archive of contemporary and historical data, including access to market intelligence and thought leadership, to deliver the most accurate, timely and comprehensive view of pharma assets in development.

Built on the same platform as EvaluatePharma, Evaluate Omnium allows easy incorporation of consensus and proprietary analytics, enabling you to create an informed, confident perspective on the pharma development landscape.

REQUEST A DEMO